NEWTON, Mass., Oct. 05, 2018 (GLOBE NEWSWIRE) — Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing with Priority Review its…Original Article
U.S. FDA Accepts Karyopharm’s New Drug Application for Selinexor and Grants Priority Review
